Press Release

Date: 25.08.2026 The Manager The Manager, BSE Limited NSE Limited, P. J. Towers, Dalal Street Exchange Plaza, Bandra Kurla Complex, Mumbai-400001 Bandra (E), Mumbai- 400051. (BSE Scrip Code: 544742) (NSE Symbol: SAIPARENT) Dear Sir/Madam, Unit: Sai Parenterals Limited Subject: Press Release- Disclosure under Reg. 30 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015. Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith a copy of the Press Release titled: Sai Parenterals' Australian Subsidiary, Noumed Pharmaceuticals, Renews its OTC Supply Agreement with one of Australia's Leading Pharmacy Networks in a 3-Year Deal Valued at Australian Dollars (AUD) 30 million (Equivalent to INR 204 crores; 1AUD = INR 68.52) Request you to kindly take the same on record. Thanking you, Yours faithfully, For Sai Parenterals Limited Mr. Anil Kumar Karusala Managing Director (DIN- 01866646) Encl: As above Investor Release Sai Parenterals Limited Noumed Renews 3-Year OTC Supply Agreement, Valued at AUD 30 Million Hyderabad, 25th August 2026 – Sai Parenterals Limited, an Integrated CDMO and branded generics enterprise, has announced that its Australian subsidiary, Noumed Pharmaceuticals Pty Ltd, has renewed its OTC Medicines Supply Agreement with one of Australia's leading, multi-billion-dollar pharmacy chains. The renewal carries an expanded product portfolio, a long agreement tenure and a higher agreement value, and is projected at AUD 30 million (approximately INR 204.0 crore; 1 AUD = INR 68) over a three-year term, effective immediately. That translates to about AUD 10 million a year, and the agreement is structured for continuous growth: new product development and line extensions are to be added over its term,steadilywideningtheportfolio itcovers. Noumed will continue to manage the full value chain — manufacturing, product sourcing, regulatory compliance, TGA registrations, warehousing, quality assurance and nationwide distribution — entrusted to a single accountable partner. Noumed owns the product registrations and holds the marketing authorization, while the pharmacy chain retails the productunderitsownconsumerbrand. The renewal further cements Noumed’s position in the Australian OTC market and confirms the trust placed in its regulatory, quality and supply-chain capabilities in one of the most discerning andtightly regulatedmarketsintheworld. For Sai Parenterals, it improves utilisation of the Group’s regulatory and manufacturing infrastructure, strengthens longer-duration earnings visibility from recurring OTC business, and provides a further platform for expansion into additional regulated international markets. Togetherwiththe 7½-year agreement renewedon 1stJuly2026, valuedatAUD202million (approximatelyINR1,300crore),theAustralianOTCbooknowstandsatAUD232millionof contractedsupply,orapproximatelyINR1,506croreinaggregate. Volumes under these agreements are today largely sourced from third-party manufacturers, on which Noumed earns a distribution margin. As the Adelaide facility commissions and Indian capacity expands, that production progressively moves in-house, converting a distribution margin into a manufacturing margin on the same contracted revenue. This Long-Term Agreement further demonstrates the distinct advantage of our CDMO platform. Beyond securing long-term revenue certainty, this also stands as a testament toourcapabilities,andthetrustcustomersplaceinus. Investor Release Commenting on the development, Mr. Anil Kumar Karusala, Chairman and Managing Director,SaiParenteralsLimited,said: "Noumed has renewed two supply agreements in the space of two months. Together they take our contracted OTC book in Australia to AUD 232 million, close to INR 1,506 crore in aggregate. These are renewals earned over years of consistent delivery in one of the most tightly regulated markets in the world and they are the reason we acquired the Noumed Platform. Product under these agreements is today largely sourced from third-party manufacturers, and Noumed earns a distribution margin on it. As our Adelaide facility commissions and our Indian capacity expands, that production moves in-house — the same contracted revenue shall earnatamanufacturingmarginratherthanadistribution margin.” Mr.MarkThulborne,ChiefExecutiveOfficer,NoumedPharmaceuticalsPtyLtd,added: "This renewal reflects the depth of our product range and the confidence our customers place in our ability to supply without interruption. We hold the registrations, we hold the inventory and we shall manage everything from sourcing and regulatory compliance through to nationwide distribution. Our customers value having that entire chain with one accountablepartnerandtheyhavechosentoextendit. The agreement is built to grow, with new product development and line extensions to be added over its term. As local manufacturing at Adelaide comes on stream, we will shorten leadtimes,reducetheinventoryweareobligedtocarryandservethesepartnersbetterthan anyoffshoresupplychainallows." Investor Release AbouttheCompany Sai Parenterals Limited is an integrated, IP-led pharmaceutical enterprise operating across two complementary verticals — contract development and manufacturing for Indian and multinational customers, and branded generic formulations sold domestically and exported into regulatedandsemi-regulatedmarkets.TheCompany’sportfoliospans302commercialproducts across nine therapeutic areas, supported by 599 approved registrations and 67 dossiers under development, and is manufactured across six facilities, five in India and one in Australia, carrying GMP, WHO-GMP, TGA-Australia and PIC/S accreditations. Through Noumed Pharmaceuticals in Australia and New Zealand, acquired in November 2025, the Company holds one of Australia’s largest private-label OTC portfolios, with 15 exclusive long-term supply agreements covering526 SKUs and a library of over 451 TGA-approved dossiers. More than 50% of consolidated revenue is contracted under long-term regulated-market agreements. The Company completed its initial publicofferinginMarch2026andwaslistedontheBSEandtheNSEonApril02,2026. SafeHarbor Statements in this document relatingtofuturestatus, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project relatedissues areforward-lookingstatementsbased on estimates and theanticipatedeffects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changedassumptionsorotherfactors. For more information, please contact Company: Investor Relations (IR) Sai Parenterals Limited Strategic Growth Advisors Pvt. Ltd. CIN:U24231TG2001PLC036043 CIN: U74140MH2010PTC204285 Mr.AnilKumar,CFO Ms.DrashtiShah/Mr.ParinNarichania ir@saiparenterals.com drashti.shah@sgapl.net/parin.n@sgapl.net +918767224443 /+919930025733 saiparenterals.com www.sgapl.net